ObjectiveTo analyze the clinical effect of transrectal ultrasound-guided prostate therapy device combined with levofloxacin in the treatment of prostatitis.
MethodsA total of 190 patients with prostatitis were randomly divided into the control group(n=95) and observation group(n=95).The control group and observation group were treated with levofloxacin intravenous infusion and rectal prostate therapy device combined with levofloxacin rectal introduction, respectively.The cure rate, total effective rate and recurrence rate in two groups were analyzed.The levels of chronic prostatitis symptoms(NIH-CPSI) score, maximum urine flow rate(MFR), and average urine flow rate(AFR), secretory immunoglobulin A(SIgA), macrophage inflammatory protein 1α(MIP-1α), macrophage inflammatory protein-2(MIP-2), interleukin-2(IL-2), IL-6 and vascular cell adhesion molecule-1(VCAM-1) between two groups before and after treatment were compared.
ResultsThe cure rate and total effective rate in observation group were significantly higher than those in control group(P < 0.01), and the recurrence rate in observation group was significantly lower than that in control group(P < 0.01).After treatment, the scores of pain symptoms, urinary symptoms, symptom severity and quality of life in observation group were significantly lower than those in control group(P < 0.01), and the levels of MFR and AFR in observation group were significantly higher than in control group(P < 0.01).After treatment, the levels of MIP-1α, MIP-2, SIgA, VCAM-1, IL-2 and IL-6 in observation group were significantly lower than those in control group(P < 0.01).
ConclusionsTransrectal ultrasound-guided prostate therapy combined with levofloxacin in the treatment of prostatitis can alleviate the clinical symptoms, improve the local immune-mediated inflammatory response of prostate, improve the cure rate, and reduce the recurrence rate.
DownLoad: